| Literature DB >> 21904618 |
Yang Li1, Chengxing Shen, Yanan Ji, Yi Feng, Genshan Ma, Naifeng Liu.
Abstract
BACKGROUND: Coronary tortuosity (CT) is a common coronary angiography finding. The exact pathogenesis, clinical implication and long-term prognosis of CT are not fully understood. The purpose of this study is to investigate the clinical characteristics of CT in patients with suspected coronary artery disease (CAD) in a Chinese population.Entities:
Mesh:
Year: 2011 PMID: 21904618 PMCID: PMC3164184 DOI: 10.1371/journal.pone.0024232
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow diagram of patient follow-up.
Figure 2Diagnosis of coronary tortuosity.
Clinical characteristics of coronary tortuosity.
| Characteristic | CT group(n = 395) | NCT group(n = 615) | p value |
| age(year) | 64±10. 3 | 64±10. 7 | 0. 690 |
| female gender | 247 (62. 8) | 218 (35. 4) | <0. 001 |
| hypertension | 300 (75. 9) | 423 (68. 8) | 0. 014 |
| diabetes mellitus | 71 (18. 0) | 141 (22. 9) | 0. 059 |
| hyperlipidemia | 68 (17. 2) | 130 (21. 1) | 0. 125 |
| cigarette smoking | 72 (18. 2) | 225 (36. 6) | <0. 001 |
| chronic heart failure | 64 (16. 2) | 106 (17. 2) | 0. 668 |
| CAD | 196 (49. 6) | 373 (60. 7) | 0. 001 |
Multivariate logistic regression analysis of selected variables for coronary tortuosity.
| Variable | B | SE |
| P value | OR | 95%CI |
| female | 0. 957 | 0. 166 | 33. 083 | <0. 001 | 2. 603 | 1. 897–3. 607 |
| hypertension | 0. 427 | 0. 155 | 7. 598 | 0. 006 | 1. 533 | 1. 131–2. 076 |
| diabetes | −0. 353 | 0. 175 | 4. 158 | 0. 041 | 0. 702 | 0. 500–0. 986 |
| hyperlipidemia | −0. 421 | 5. 787 | 5. 787 | 0. 016 | 0. 657 | 0. 466–0. 925 |
| CAD | −0. 48 | 0. 140 | 4. 023 | 0. 045 | 0. 755 | 0. 574–0. 994 |
Multivariate logistic regression analysis of selected variables for LAD tortuosity.
| Variable | B | SE |
| P value | OR | 95%CI |
| female | 1. 040 | 0. 165 | 39. 929 | <0. 001 | 2. 830 | 2. 049–3. 907 |
| hypertension | 0. 612 | 0. 194 | 9. 963 | 0. 002 | 1. 844 | 1. 261–2. 697 |
| LAD≥50% stenosis | −0. 192 | 0. 210 | 97. 095 | <0. 001 | 0. 755 | 0. 574–0. 994 |
Baseline characteristics of the patients with CAD followed up.
| Characteristic | CT group(n = 137) | NCT group(n = 271) | p value |
| age(year) | 68±8.9 | 66±10.6 | 0. 163 |
| female gender | 74(54.0) | 85(31.4) | <0. 001 |
| medical history | |||
| hypertention | 112(81.8) | 194(71.6) | 0. 025 |
| diabetes mellitus | 32(23.4) | 82(30.3) | 0. 142 |
| hyperlipemia | 21(15.3) | 59(21.8) | 0. 122 |
| cigarette smoking | 33(24.1) | 112(41.3) | 0. 001 |
| heart failure | 29(21.2) | 52(19.2) | 0. 636 |
| previous myocardial infarction | 33(24.1) | 68(25.1) | 0. 824 |
| previous coronary revascularization | |||
| PCI | 86(62. 8) | 177(65.3) | 0. 613 |
| Coronary-artery bypass grafting | 2(1.5) | 3(1.1) | 0. 760 |
| No. of vessel (≥50% stenosis) | |||
| One vessel | 71(51.8) | 119(43.9) | 0.130 |
| Two vessel | 37(27.0) | 64(23.6) | 0.454 |
| Three vessel | 29(21.2) | 88(32.5) | 0.017 |
| asprin therapy | 115(83.9) | 228(84.1) | 0. 960 |
| clopidogrel therapy | 135(98.5) | 267(98.5) | 0. 990 |
| statin therapy | 75(54.7) | 138(50.9) | 0. 465 |
| beta-blockers therapy | 66(48.2) | 127(46.9) | 0. 802 |
| calcium channel blocker | 72(52.6) | 136(50.2) | 0.651 |
| ACEI/ARB therapy | 78(56.9) | 142(52.4) | 0. 385 |
Baseline characteristics of the patients without CAD followed up.
| Characteristic | CT group(n = 165) | NCT group(n = 202) | p value |
| age(year) | 61±10.8 | 60±10.8 | 0.787 |
| female gender | 111(67.3) | 89(44.1) | <0.001 |
| medical history | |||
| hypertention | 115(69.7) | 131(64.9) | 0.326 |
| diabetes mellitus | 17(10.3) | 33(16.3) | 0.094 |
| hyperlipemia | 23(13.9) | 38(18.8) | 0.212 |
| cigarette smoking | 23(13.9) | 60(29.7) | <0.001 |
| heart failure | 14(8.5) | 30(14.9) | 0.062 |
| aspirin therapy | 74(44.8) | 103(51.0) | 0.241 |
| statin therapy | 22(13.3) | 30(14.9) | 0.678 |
| beta-blockers therapy | 25(15.2) | 28(13.9) | 0.727 |
| calcium channel blocker | 48(29.1) | 75(37.1) | 0.105 |
| ACEI/ARB therapy | 42(25.5) | 65(32.2) | 0.159 |
Major adverse cardiovascular events of the patients followed-up.
| MACE | CAD Patients(n = 408) | Non CAD Patients(n = 367) | ||||
| CT group(n = 137) | NCT group(n = 271) | p value | CT group(n = 165) | NCT group(n = 202) | p value | |
| the primary end point | ||||||
| cardiac death | 2(1.5) | 6(2.2) | 0.604 | 1(0.6 ) | 1(0.5 ) | 0.886 |
| cardiac death due to CAD | 1(0.7) | 6(2.2) | 0.276 | 0(0) | 1(0.5) | 0.365 |
| acute myocardial infarction | 5(3.6) | 13(4.8) | 0.594 | 0(0 ) | 2(1.0) | 0.200 |
| the secondary end point | ||||||
| all cause mortality | 4(2.9) | 10(3.7) | 0.686 | 2(1.2) | 3(1.5) | 0.822 |
| coronary revascularization | 13(9.5) | 39(14.4) | 0.161 | 1(0.6 ) | 1(0.5) | 0.886 |
| non-fatal angina needing hospital admission | 50(36.5) | 103(38.0) | 0.766 | 1(0.6 ) | 1(0.5) | 0.886 |
| stroke | 12(8.8) | 33(12.7) | 0.298 | 7(4.2) | 9(4. 5) | 0.921 |
| composite end point | 55(40.1) | 130(48.0) | 0.134 | 11(6.7) | 13(6.4) | 0.929 |
Major adverse cardiovascular events of the patients with CAD followed-up.
| MACE | Male (n = 249) | Female(n = 159) | ||||
| CT group(n = 63) | NCT group(n = 186) | p value | CT group(n = 74) | NCT group(n = 85) | p value | |
| the primary end point | ||||||
| cardiac death | 0(0) | 3(1.6) | 0.311 | 2(2.7 ) | 3(3.5 ) | 0.766 |
| cardiac death due to CAD | 0(0) | 3(1.6) | 0.311 | 1(1.4) | 3(3.5) | 0.382 |
| acute myocardial infarction | 2(3.2) | 11(5.9) | 0.398 | 3(4.1 ) | 2(2.4) | 0.540 |
| the secondary end point | ||||||
| all cause mortality | 1(1.6) | 6(3.2) | 0.496 | 3(4.1) | 4(4.7) | 0.842 |
| coronary revascularization | 6(9.5) | 24(12.9) | 0.476 | 7(9.5 ) | 15(17.6) | 0.136 |
| non-fatal angina needing hospital admission | 23(36.5) | 74(39.8) | 0.645 | 27(36.5 ) | 29(34.1) | 0.755 |
| stroke | 6(9.5) | 23(12.4) | 0.543 | 6(8.1) | 10(11. 8) | 0.445 |
| composite end point | 26(41.3) | 89(47.8) | 0.365 | 31( 41.9) | 36(42.4) | 0.953 |